Cancervax Files Non-Provisional Patent for Universal Cancer Treatment

The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies to develop a breakthrough universal cancer treatment LEHI, Utah, March 16, 2023 (GLOBE NEWSWIRE) -- Cancervax, Inc., a pre-clinical biotechnology company creating a better way to treat cancer, the developer of a breakthrough universal cancer treatment that will use the body’s immune system to treat cancer, announced that it has recently filed a non-provisional patent application to protect its invention which leverages cutting-edge bioengineering techniques such as CRISPR and mRNA to develop a breakthrough universal cancer treatment. “This is a very important milestone for us,” said Ryan Davies, Cancervax CEO. “We previously filed a confidential provisional patent in October 2021 with the U.S. Patent and Trademark Office (USPTO) for our breakthrough universal cancer treatment. Our regular utility patent application (nonprovisional) will now allow the USPTO to formally review our invention claims. If any claims are granted, we will have patent protection starting from the October 2021 provisional filing date.” Mr. Davies stated, “As we previously announced, our plan is to leverage existing cutting-edge biotechnologies, such as CRISPR and mRNA, to develop a breakthrough universal cancer treatment. Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, we are developing cancer vaccines that will similarly leverage the body’s immune system to target and destroy cancer cells.” “Conventional cancer immunotherapy is based on finding protein markers or mechanisms that are naturally expressed in cancer cells and then developing custom antibodies or immune cells to target those specific protein markers for cell destruction,” Mr. Davies continued. “The main challenge with this approach is that human biology is not very predictable, and the natural protein markers often appear in healthy normal cells as well. As a result, any treatment targeting those natural markers often also affect normal cells. It is only through extensive human clinical trials that one can determine if a particular treatment is viable.” Mr. Davies concluded, “Instead, we plan to engineer a custom, non-naturally occurring protein marker for cancer cells to express, and then vaccinate against that. We believe that this is a novel approach which could help overcome cancer, a disease that according to the World Health Organization, is the second cause of death in the world.” For more information about Cancervax, please visit https://www.cancervax.com/ . About CancerVax CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases, such as measles or chickenpox, we intend to use the body’s natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot — a better way to fight cancer. To learn more, please visit www.CancerVax.com Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Press Contact: Cancervax, Inc. Tel: (805) 356-1810 [email protected]

The release as fetched from its publisher. cancervax.com ↗